featured
Brentuximab Vedotin With Chemotherapy in Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
J. Clin. Oncol 2021 Apr 28;[EPub Ahead of Print], A Kumar, C Casulo, RH Advani, E Budde, PM Barr, CL Batlevi, P Caron, LS Constine, SV Dandapani, E Drill, P Drullinsky, JW Friedberg, C Grieve, A Hamilton, PA Hamlin, RT Hoppe, SM Horwitz, A Joseph, N Khan, L Laraque, MJ Matasar, AJ Moskowitz, A Noy, ML Palomba, H Schöder, DJ Straus, S Vemuri, J Yang, A Younes, AD Zelenetz, J Yahalom, CH MoskowitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.